State Bills Setting Specialty Tier Limits Await Health Reform Developments
Executive Summary
Legislation is pending in a number of states that would ban or set limits around the use of formulary specialty tiers in private insurance. However, most of the bills appear to be on hold pending implementation over the next six to eight months of new insurance requirements under the health reform law.
You may also be interested in...
USP Formulary Guidelines Back In Spotlight With Essential Health Benefits Proposal
HHS proposes to use USP’s drug classification system, created as a guideline for Medicare Part D formularies, to facilitate “review, analysis and comparison” of the breadth of drug coverage offered by individual and small group private insurance plans beginning in 2014.
Paying For Essentials: Fight Brewing Over Specialty Tiers In Exchange Plans
Biopharmaceutical companies, patient groups and other stakeholders are pushing for federal guidelines specifically barring the use of formulary specialty tiers in private health insurance plans for individuals and small groups.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.